Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 1;4(9):e180174.
doi: 10.1001/jamaoncol.2018.0174. Epub 2018 Sep 13.

Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast Density

Affiliations

Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast Density

Adam R Brentnall et al. JAMA Oncol. .

Abstract

Importance: Accurate long-term breast cancer risk assessment for women attending routine screening could help reduce the disease burden and intervention-associated harms by personalizing screening recommendations and preventive interventions.

Objective: To report the accuracy of risk assessment for breast cancer during a period of 19 years.

Design, setting, and participants: This cohort study of the Kaiser Permanente Washington breast imaging registry included women without previous breast cancer, aged 40 to 73 years, who attended screening from January 1, 1996, through December 31, 2013. Follow-up was completed on December 31, 2014, and data were analyzed from March 2, 2016, through November 13, 2017.

Exposures: Risk factors from a questionnaire and breast density from the Breast Imaging and Reporting Data System at entry; primary risk was assessed using the Tyrer-Cuzick model.

Main outcomes and measures: Incidence of invasive breast cancer was estimated with and without breast density. Follow-up began 6 months after the entry mammogram and extended to the earliest diagnosis of invasive breast cancer, censoring at 75 years of age, 2014, diagnosis of ductal carcinoma in situ, death, or health plan disenrollment. Observed divided by expected (O/E) numbers of cancer cases were compared using exact Poisson 95% CIs. Hazard ratios for the top decile of 10-year risk relative to the middle 80% of the study population were estimated. Constancy of relative risk calibration during follow-up was tested using a time-dependent proportional hazards effect.

Results: In this cohort study of 132 139 women (median age at entry, 50 years; interquartile range, 44-58 years), 2699 invasive breast cancers were subsequently diagnosed after a median 5.2 years of follow-up (interquartile range, 2.4-11.1 years; maximum follow-up, 19 years; annual incidence rate [IR] per 1000 women, 2.9). Observed number of cancer diagnoses was close to the expected number (O/E for the Tyrer-Cuzick model, 1.02 [95% CI, 0.98-1.06]; O/E for the Tyrer-Cuzick model with density, 0.98 [95% CI, 0.94-1.02]). The Tyrer-Cuzick model estimated 2554 women (1.9%) to be at high risk (10-year risk of ≥8%), of whom 147 subsequently developed invasive breast cancer (O/E, 0.79; 95% CI, 0.67-0.93; IR per 1000 women, 8.7). The Tyrer-Cuzick model with density estimated more women to be at high risk (4645 [3.5%]; 273 cancers [10.1%]; O/E, 0.78; 95% CI, 0.69-0.88; IR per 1000 women, 9.2). The hazard ratio for the highest risk decile compared with the middle 80% was 2.22 (95% CI, 2.02-2.45) for the Tyrer-Cuzick model and 2.55 (95% CI, 2.33-2.80) for the Tyrer-Cuzick model with density. Little evidence was found for a decrease in relative risk calibration throughout follow-up for the Tyrer-Cuzick model (age-adjusted slope, -0.003; 95% CI, -0.018 to 0.012) or the Tyrer-Cuzick model with density (age-adjusted slope, -0.008; 95% CI, -0.020 to 0.004).

Conclusions and relevance: Breast cancer risk assessment combining classic risk factors with mammographic density may provide useful data for 10 years or more and could be used to guide long-term, systematic, risk-adapted screening and prevention strategies.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Drs Cuzick and Brentnall report receiving royalty payments through Cancer Research UK for commercial use of the Tyrer-Cuzick algorithm. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Observed Cumulative Invasive Breast Cancer Risk by 10-Year Risk Group
The risk groups are from the 10-year risk assessment. The width of the fan represents a pointwise 95% CI. At 10 years the observed risk for the Tyrer-Cuzick model and the Tyrer-Cuzick model with density was 1.8% and 1.6%, respectively, for the group with predicted risk of less than 2%; 2.6% and 2.6%, respectively, for predicted risk of 2% to less than 3%; 4.1% and 3.8%, respectively, for predicted risk of 3% to less than 5%; 5.5% and 5.4%, respectively, for predicted risk of 5% to less than 8%; and 8.2% and 9.0%, respectively, for predicted risk of 8% or greater.
Figure 2.
Figure 2.. Observed and Expected Cumulative Invasive Breast Cancer Risk by Quantile
The risk groups are from the predicted 10-year risk assessment (lowest decile, middle 80% and top decile). Solid lines indicate observed risk; broken lines, expected risk. At 10 years the observed risk for the Tyrer-Cuzick model and the Tyrer-Cuzick model with density was 1.4% and 1.0%, respectively, for the bottom decile of risk; 2.7% and 2.6%, respectively, for the middle 80% of risk; and 5.9% and 7.0%, respectively, for the top decile of risk.

Comment in

References

    1. Ferlay J, Soerjomataram I, Ervik M, et al. , eds. GLOBOCAN 2012: Estimated Cancer Incidence and Mortality Worldwide in 2012, version 1.0. IARC Cancer Base 11. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr. Accessed July 23, 2014.
    1. Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening. Br J Cancer. 2013;108(11):-. - PMC - PubMed
    1. Massat NJ, Dibden A, Parmar D, Cuzick J, Sasieni PD, Duffy SW. Impact of screening on breast cancer mortality. Cancer Epidemiol Biomarkers Prev. 2016;25(3):455-462. - PubMed
    1. Cuzick J, Sestak I, Bonanni B, et al. ; SERM Chemoprevention of Breast Cancer Overview Group . Selective oestrogen receptor modulators in prevention of breast cancer. Lancet. 2013;381(9880):1827-1834. - PMC - PubMed
    1. Gail MH, Brinton LA, Byar DP, et al. . Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879-1886. - PubMed